CCR9 Recombinant Monoclonal Antibody

說明書

中文名稱：

CCR9重組抗體
貨號：

CSB-RA004848MA1HU
規(guī)格：

￥1320
圖片：
The Binding Activity of CCR9 with Anti-CCR9 recombinant antibody
Activity: Measured by its binding ability in a functional ELISA. Immobilized Human CCR9 at 10 μg/mL can bind Anti-CCR9 recombinant antibody (CSB-RA004848MA1HU). The EC₅₀ is 31.67-36.83 ng/mL. The VLPs (CSB-MP3838) is negative control.
其他：

產(chǎn)品詳情
產(chǎn)品評價
相關(guān)產(chǎn)品
靶點(diǎn)詳情

產(chǎn)品詳情

產(chǎn)品描述：

CSB-RA004848MA1HU CCR9重組單克隆抗體是一款經(jīng)ELISA驗(yàn)證的高特異性科研工具，靶向趨化因子受體CCR9。該受體屬于G蛋白偶聯(lián)受體超家族，選擇性表達(dá)于腸道歸巢T淋巴細(xì)胞及樹突狀細(xì)胞表面，通過介導(dǎo)CCL25趨化信號參與腸道免疫調(diào)節(jié)及炎癥反應(yīng)，其功能異常與炎癥性腸病、乳糜瀉等病理過程密切相關(guān)。本抗體采用重組技術(shù)制備，具有嚴(yán)格的批次一致性，在ELISA實(shí)驗(yàn)中展現(xiàn)出優(yōu)異的抗原結(jié)合能力，可精準(zhǔn)識別天然構(gòu)象的CCR9蛋白，適用于體外檢測靶蛋白表達(dá)水平、篩選配體相互作用或評估受體活性調(diào)控機(jī)制。該產(chǎn)品可為腸道黏膜免疫研究、炎癥性疾病動物模型構(gòu)建及藥物靶點(diǎn)驗(yàn)證等實(shí)驗(yàn)提供可靠支持，尤其適用于探索CCR9在免疫細(xì)胞遷移、黏膜屏障穩(wěn)態(tài)維持中的分子機(jī)制。
Uniprot No.：

P51686
基因名：

CCR9
別名：

CCR9 antibody; GPR28 antibody; C-C chemokine receptor type 9 antibody; C-C CKR-9 antibody; CC-CKR-9 antibody; CCR-9 antibody; G-protein coupled receptor 28 antibody; GPR-9-6 antibody; CD antigen CDw199 antibody
反應(yīng)種屬：

Human
免疫原：

Recombinant Human CCR9 protein
免疫原種屬：

Homo sapiens (Human)
標(biāo)記方式：

Non-conjugated
克隆類型：

Monoclonal
抗體亞型：

hIgG1
純化方式：

Affinity-chromatography
克隆號：

8H4
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
產(chǎn)品提供形式：

Liquid
應(yīng)用范圍：

ELISA
Protocols：

ELISA Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評價

靶點(diǎn)詳情

功能：

Receptor for chemokine SCYA25/TECK. Subsequently transduces a signal by increasing the intracellular calcium ions level.; (Microbial infection) Alternative coreceptor with CD4 for HIV-1 infection.
基因功能參考文獻(xiàn)：
1. There were significantly increased CCR9 protein levels in failing human hearts. PMID: 27146447
2. this study showed that CCR7 are overexpressed in CD4(-) CD8(-) thymocytes of myasthenia gravis patients. PMID: 26616645
3. Results indicated that the expression levels of CCR9 in lesional skin may be a useful biologic marker of the clinical efficacy of infliximab therapy in psoriasis patients. PMID: 26507968
4. Xray crystal structure of the CCR9 receptor in complex with vercirnon at 2.8 A resolution PMID: 27926729
5. It plays a pathogenic role in liver diseases and it will be a therapeutic target of the diseases. PMID: 27795503
6. that CCL25/CCR9 signal may provide cancer cells with chemotactic abilities through influencing several epithelial-mesenchymal transitionmarkers PMID: 27008282
7. Studies indicate important roles played by chemokine ligand 25 (CCL25)/chemokine receptor 9 (CCR9) in tumorigenesis, tumor chemoresistance and metastasis. PMID: 26879872
8. CCR9 and Integrin-beta7 expression has a differential effect on graft fate during acute graft-versus-host disease (GVHD) of the liver depending on the GVHD target tissue. PMID: 26348893
9. CCR9 mRNA and protein levels were significantly increased in the nasopharyngeal carcinoma group compared with the control group. PMID: 26279399
10. CCR9-CCL25 interaction promoted proliferation and suppressed apoptosis of non-small cell lung cancer cells by activating the PI3K/Akt pathway. PMID: 25691296
11. CCR9 could be beneficial in predicting lymph node metastasis, and it might act as a novel prognostic biomarker for lung adenocarcinoma. PMID: 26168791
12. We also show that primary tumors can be modeled in immunocompetent mice by microinjecting CCR9-expressing cancer cell lines into early-stage mouse blastocysts, which induces central immune tolerance PMID: 26006007
13. High CCR9 expression is associated with the pathogenesis of ulcerative colitis. PMID: 24936795
14. Expression of CCR9 and CCL25, the only natural ligand of CCR9, was significantly higher (p<0.0001) in NSCLC tissues and serum respectively, compared to their respective controls. PMID: 25296976
15. activation of Notch1 has a dominant-negative effect on Ccr9 transcription and that Notch1 and E proteins control the dynamic expression of Ccr9 during T cell development. PMID: 25710912
16. The results show the potential of the 91R monoclonal antibody as a therapeutic agent for treatment of CCR9-expressing tumors. PMID: 24870448
17. results suggest that CCR9 can act as a novel prognostic marker and therapeutic target for hepatocellular carcinoma PMID: 24481516
18. CCR9 expression is elevated in the nodal lymphomas of patients with GI involvement PMID: 24828696
19. Only rotavirus specific CD4 T cells expressed intestinal homing receptors alpha4beta7 and CCR9. PMID: 24606696
20. Data suggest that P-glycoprotein associate with the F-actin cytoskeleton through ezrin/radixin/moesin (ERM) in CCR9/CCL25 induced multidrug resistance of acute T-lymphocytic leukemia (T-ALL) cells. PMID: 23326330
21. Notch1 regulates chemotaxis and proliferation by controlling the CC-chemokine receptors 5 and 9 in T cell acute lymphoblastic leukaemia. PMID: 21984373
22. We provide the first evidence that CCR9 and its natural ligand CCL25 are highly expressed by ovarian cancer tissue and their expression correlates with histological subtypes. PMID: 21637913
23. CCL25 enhanced the expression of MMP-1, -9, -11 and -13 active proteins by BrCa cells in a CCR9-dependent fashion. PMID: 21344163
24. CCR9+ Th cells are a subset of IL-21-producing T helper cells that influence regional specification of autoimmune diseases that affect accessory organs of the digestive system PMID: 21511186
25. The high fraction of circulating IgA+ and IgG+ B cells expressing CCR9 and CCR10 in the first months of life indicates activation of naive B cells in the gut, coinciding with bacterial colonization. PMID: 21075690
26. TLR2 ligands induce CCR9 and CCR10 expression by circulating B-cells and increase their chemotaxis. TLR2 stimulation also induced J chain and IgA production demonstrating the induction of mucosal-like antibody secreting cells. PMID: 20947433
27. CCR9 expression by monocytes is increased in rheumatoid arthritis PMID: 20738854
28. Results demonstrate enhanced pancreatic intraepithelial neoplasia and pancreatic cancer cell proliferation with activation of CCR9 by its selective ligand CCL25 PMID: 19756884
29. Studies indicate that D6 chemokine receptor(CCR-9) may act as scavenging decoys and are involved in clearance of chemokines. PMID: 20036838
30. more active homing of CCR9-926AG T cells to Peyer's patches may produce changes in Ag presentation and result in increased incidence of skin graft vs. host disease. PMID: 19525985
31. over-expressed TECK interacts with CCR9 on the endometrial stromal cells in the endometriotic milieu, which may contribute to the onset and progression of endometriosis. PMID: 20081876
32. A subset of CCR9+ T cells from normal donors has characteristics of mucosal T cells in terms of activated phenotype, proliferative response to anti-CD2 stimulation, a Th1 or Tr1 cytokine profile, and support for Ig production by cocultured B cells. PMID: 12816994
33. CCR9 selectively induced T-ALL CD4+ T-cell chemotaxis and adhesion. PMID: 14559839
34. High Expression of CCR9 is associated with prostate cancer cell migration and invasion PMID: 15623660
35. involved in the pathogenesis of lymphatic filarial disease PMID: 15717282
36. CCR9 overexpression is associated with Adult T-cell leukemia cells infiltrating gastrointestinal tract PMID: 17205512
37. CCR9 expression is reduced on epithelial and lamina propria T cells in untreated celiac disease. Down-regulation of CCR9 persists in intraepithelial T cells from well-treated patients. Possible ongoing immune activation preferentially within epithelium. PMID: 17570212
38. CCR9 is expressed on human melanoma cells and participates in the enhanced motility of melanoma cells and is likely a "homing receptor" for melanoma to the small bowel. PMID: 18245518
39. Functionally active CCR9 on melanoma cells facilitates metastasis to the small intestine which may explain high incidence of metastis to the small intestine. PMID: 18245522
顯示更多

收起更多
亞細(xì)胞定位：

Cell membrane; Multi-pass membrane protein.
蛋白家族：

G-protein coupled receptor 1 family
組織特異性：

Highly expressed in the thymus and low in lymph nodes and spleen.
數(shù)據(jù)庫鏈接：

HGNC: 1610

OMIM: 604738

KEGG: hsa:10803

STRING: 9606.ENSP00000350256

UniGene: Hs.225946

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human